Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575982 | 0.76 | TSHR (0.60) | HTR2ATDP1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL5774079 | 0.73 | HRH3 (0.53) | HRH3HTR2AHTR7HTR6TDP1 | |
| SCHEMBL8780187 | 0.72 | TDP1 (1.00) | HRH3HTR2AHTR7HTR6TDP1 | |
| Hydrochloric Acid SCHEMBL8780151 | 0.72 | HRH3 (0.97) | HRH3HTR2AHTR7HTR6TDP1 | |
| SCHEMBL5746363 | 0.72 | TDP1 (0.53) | HRH3HTR2AHTR7HTR6TDP1 | |
| SCHEMBL7141863 | 0.71 | MAOB (0.41) | CYP2D6KMT2AKDM4EPARP1 | |
| SCHEMBL8780201 | 0.71 | HRH3 (0.97) | HRH3HTR2AHTR7HTR6TDP1 | |
| SCHEMBL491876 | 0.71 | HRH3 (0.97) | HRH3HTR2AHTR7HTR6TDP1 | |
| SCHEMBL3577690 | 0.71 | KDM4E (0.61) | HRH3HTR2AHTR7HTR6TDP1 | |
| Oxalic Acid SCHEMBL8780050 | 0.71 | HRH3 (0.83) | HRH3HTR2AHTR7HTR6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9623008-B2 | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers | STC.UNM (US) | 2017-04-18 | — | — | US | claimed |
| US-20160184356-A1 | ARSENIC-BASED TREATMENT OF CANCERS AND INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | claimed |
| US-9132120-B1 | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers | STC.UNM (US) | 2015-09-15 | — | — | US | claimed |
| US-20090170860-A1 | Use of PARP-1 Inhibitors | PHARMA MAR, S.A., SOCIEDAD UNIPERSONAL (ES) | 2009-07-02 | — | — | US | claimed |
| US-20060079510-A1 | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis | MAXIM PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | claimed |
| US-12551498-B2 | Treatment of P53-deficient cancers | HEALTH RESEARCH, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-11944615-B2 | Combination therapy for treatment of LKB1 deficient cancers | NEW YORK UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230226047-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCERS | HEALTH RESEARCH, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220249531-A1 | TREATMENT OF P53-DEFICIENT CANCERS | HEALTH RESEARCH, INC. | 2022-08-11 | — | — | US | disclosed |
| US-20220062260-A1 | COMBINATION THERAPY FOR TREATMENT OF LKB1 DEFICIENT CANCERS | NEW YORK UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| US-10086010-B2 | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | STC.UNM (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180221382-A1 | INHIBITION OF MK2 IN THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS | 2018-08-09 | — | — | US | disclosed |
| US-20180125875-A1 | SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2018-05-10 | — | — | US | disclosed |
| US-9623008-B2 | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers | STC.UNM (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160184356-A1 | ARSENIC-BASED TREATMENT OF CANCERS AND INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| US-9132120-B1 | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers | STC.UNM (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2389589-B1 | METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS | BRIGHAM & WOMENS HOSPITAL (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140343095-A1 | Methods of Diagnosing and Treating Multiple Sclerosis | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20090170860-A1 | Use of PARP-1 Inhibitors | PHARMA MAR, S.A., SOCIEDAD UNIPERSONAL (ES) | 2009-07-02 | — | — | US | disclosed |
| US-20060079510-A1 | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis | MAXIM PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221382-A1 | INHIBITION OF MK2 IN THE TREATMENT OF CANCER | MKNK2, MKNK1, DUSP2 | HRH3 4059/4885HTR2A 3818/4885HTR7 4445/4885 |
| US-12551498-B2 | Treatment of P53-deficient cancers | TP53, BRCA1, PARP2 | HRH3 2217/4885HTR2A 334/4885HTR7 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.